TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01083017
Drug: chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: chlorthalidone 25mg/d vs. chlorthalidone 50mg/d
Study: NCT01083017
Drug: standardized anti-hypertensive treatment
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan, amlodipine, chlorthalidone, +- spironolactone
Study: NCT03135899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses, each 12 hours apart
Study: NCT04227938
Drug: ALPN-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of ALPN-101 will be administered via intravenous infusion.
Study: NCT03802617
Drug: MR13A9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT03802617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT02139618
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03914118
Drug: Preoperative placebo + postoperative placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pre-operatively and placebo immediately post-operatively.
Study: NCT00255151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
Study: NCT01699919
Drug: Intravenous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine infusion is given in intraoperative period and till one hour post surgery.
Study: NCT00500279
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04358133
Drug: NaCl 0,9%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive placebo NaCl 0.9% administered according to the same protocol as the experimental arm
Study: NCT02555293
Drug: XIFAXAN® (Rifaximin)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02507440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
Study: NCT03392740
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given a look-alike placebo medication once a day prior to starting an anthracycline chemotherapy regimen. They will be given a new placebo medication in a step-wise fashion over period of 1 to 3 weeks.
Study: NCT03915496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as two tablets to be taken orally once daily for 12 weeks
Study: NCT04441099
Drug: NBE-002
Normalized name: BENZOCAINE 20 g in 100 g ORAL GEL [NBE Anbesol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.
Study: NCT01557842
Drug: Drug Treatment
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class I and III antiarrhythmic drug treatment.
Study: NCT00743509
Drug: Cyclophosphamide and Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The dose of cyclophosphamide will start at 200 mg (4 tablets) per day on day 1 and will be taken for 7 days every other week of a 28 day cycle.~Subjects will take 12 mg (12 tablets) of sirolimus on day 1 of treatment as a loading dose followed by 4 mg (4 tablets) daily continuously
Study: NCT02783430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single perfusion during 40 minutes at the beginning of the inclusion
Study: NCT00512707
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone Gel 1%: Starting active dose 10 g/day. Increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
Study: NCT03018171
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal
Study: NCT02533284
Drug: bupevecaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: US guided TAP using Bupevecaine 0.25 %
Study: NCT03355209
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered twice a day (BID) in equally divided doses.
Study: NCT03614494
Drug: Piroxicam 40 mg
Normalized name: piroxicam 40 MG
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Additional co-treatment
Study: NCT03348748
Drug: Stereotactic Body Radiation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo lowest-dose of SBRT
Study: NCT03348748
Drug: Stereotactic Body Radiation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo lowest- or higher-dose of SBRT
Study: NCT03348748
Drug: Stereotactic Body Radiation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo highest-dose of SBRT
Study: NCT01652729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule once daily
Study: NCT03651726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sesame oil pill manufactured to mimic 2.5 mg dronabinol capsules; cellulose pill manufactured to mimic 400 mg PEA tablets
Study: NCT00799916
Drug: Resuscitation (Voluven)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resuscitation aimed at venous oxygen saturation higher than 70%
Study: NCT00799916
Drug: Resuscitation (Saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resuscitation aimed at venous oxygen saturation higher than 70%
Study: NCT01633294
Drug: Ampicillin + gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ampicillin 1 g every six hours and gentamicin 240 mg every day intravenously
Study: NCT01120769
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT01120769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT01046630
Drug: AZD6765
Approvals — FDA: no, EMA: no, PMDA: no
Description: single infusion
Study: NCT01046630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single infusion
Study: NCT01567826
Drug: standard of care lipid therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.~Zocor, Lipitor \[any dose\] and Crestor \[less than 40mg\]
Study: NCT01567826
Drug: Aggressive lipid therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
Study: NCT01349101
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is administered on the third day after the hematopoietic stem cell transplantation (HSCT) to help reduce graft-versus-host disease (GVHD). It is given at a dose of 60 mg/kg/d for 2 days on days +3 and +4.
Study: NCT02839668
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of 1 g acetaminophen for postoperative analgesia
Study: NCT01969474
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01014962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral once daily for 5 days
Study: NCT01014962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral every 12 hours for 5 days
Study: NCT01014962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral every 8 hours for 5 days
Study: NCT02372591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
Study: NCT00793026
Drug: Dermacyd Breeze Pocket BR (Lactic Acid)
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermacyd Breeze Pocket BR (Lactic Acid) during 21 consecutive days
Study: NCT01360866
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule
Study: NCT00099268
Drug: Carbidopa/levodopa/entacapone
Normalized name: carbidopa/levodopa/entacapone 25 mg-100 mg-200 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa/Levodopa/Entacapone 12.5/50/200 mg and 25/100/200 mg capsules.
Study: NCT02173652
Drug: BI 1356, high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02173652
Drug: BI 1356, low dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03204071
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prophylaxis followed by Placebo gel to be delivered in intrabody sites of chronic periodontitis subjects.
Study: NCT02973321
Drug: SAR425899
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered by SC injection using a solution for injection in cartridge.
Study: NCT02973321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered by SC injection using a solution for injection in cartridge.
Study: NCT06132620
Drug: Femoston
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenmorphone (this product is a compound preparation, estradiol tablets contain estradiol 2mg; Estradiol dydrogesterone tablets contain estradiol 2 mg and dydrogesterone 10 mg).~Usage: 1 time/day: 1 tablet orally every day, every 28 days as a course of treatment.
Study: NCT06132620
Drug: Qingxin Zishen Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingxin Zi Kidney Decoction is a traditional Chinese medicine decoction, after regular decoction, 1 dose/day, divided into 2 doses.
Study: NCT03177382
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive another 6 cycles of CAPOX after TME.
Study: NCT02269644
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dalbavancin and linezolid randomized subjects on Day 1, 1st dose receive 500 mg of IV azithromycin
Study: NCT02827890
Drug: Januvia Tab. 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Januvia Tab. 100mg\*1T/day for 5days, QD, PO
Study: NCT02827890
Drug: Januvia Tab. 100mg + Duvie Tab. 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Januvia Tab.100mg + Duvie Tab. 0.5mg\*1T/day for 5 dyas, QD, PO
Study: NCT00004150
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004150
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01368926
Drug: RO4917523
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral doses
Study: NCT01368926
Drug: RO4917523
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple oral doses
Study: NCT01054352
Drug: JNJ38224342/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one of six (6) single ascending doses (25, 100, 300, 600, 1250 or 2000 mg) of JNJ 38224342 or matching placebo
Study: NCT00865631
Drug: NEURONTIN® 400 mg capsules, single dose (2 capsules)
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
Study: NCT01017939
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline 100 mg tablets administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
Study: NCT04659551
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamid 600 mg/mq i.v. every 3 weeks for three cycles
Study: NCT03395639
Drug: Standard of Care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care could include low molecular weight heparin (LMWH) and/or VKA according to the clinical site's SOC treatment regimen
Study: NCT02288208
Drug: Antiviral Therapy (tenofovir or entecavir)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02288208
Drug: Placebo (for birinapant)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02087176
Drug: AZD1775
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD 1775 + antimitotic agent+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
Study: NCT02087176
Drug: AZD1775 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (to match dose) + antimitotic+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
Study: NCT02087176
Drug: Antimitotic Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: The antimitotic is a drug that stops cells from dividing. This leads to cell death. Because cancer cells divide faster than normal cells, they are more likely than normal cells to be affected by this drug.
Study: NCT02155374
Drug: Intermediate acting insulin
Normalized name: Intermediate-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02155374
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (containing glucocorticoids) as prescribed by the patient's own physician
Study: NCT02390648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
Study: NCT00373191
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: N/A- not dictated by study
Study: NCT00373191
Drug: endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: N/A- not dictated by study
Study: NCT00016276
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00016276
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02406794
Drug: Neuromuscular taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
Study: NCT04470531
Drug: oral co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral co-trimoxazole + standard therapy
Study: NCT02107079
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: swallowing 1 piece, collecting saliva afterwards
Study: NCT00399737
Drug: repeated intake of fermented milk followed by a single oral dose of an ACE inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00396461
Drug: MCT/LCT (1:1)
Normalized name: lipid emulsion MCT/LCT (1:1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emulsion based on 20% MCT/LCT (50:50 ratio)
Study: NCT00396461
Drug: MCT/LCT/omega-3 (5:4:1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides.
Study: NCT01245036
Drug: Antituberculous therapy along with steroids
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: INH (300 mg/day) plus Rifampicin (450 mg/day if wt.\<50 kg and 600 mg/day if wt. \>50 kg) for six months Prednisolone 1 mg/kg/day for 6 weeks (maximum 80 mg) Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 3 months (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 3 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
Study: NCT01615887
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill
Study: NCT01983514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02450526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 Units
Study: NCT02450526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 Units
Study: NCT01001260
Drug: No ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative antiplatelet therapy instead of aspirin
Study: NCT03064438
Drug: ACCU-D1
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACCU-D1
Study: NCT03064438
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT01059786
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of infusion-related symptoms with acetaminophen is recommended.
Study: NCT04130178
Drug: Nerve block
Normalized name: Nerve Block Tray 22g
Approvals — FDA: no, EMA: no, PMDA: no
Description: block of the digital nerves in rheumatoid arthritis patient
Study: NCT02668822
Drug: ENG 125 μg + E2 300 μg vaginal ring (MK-8342B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicated vaginal ring
Study: NCT02668822
Drug: Placebo vaginal ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal ring
Study: NCT02668822
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400-mg tablets, to be taken orally, were provided to the participants for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may have taken 400 mg every 4 hours as needed for pelvic pain/cramping.
Study: NCT01059786
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Study: NCT01543555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg matching placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
Study: NCT00521989
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone
Study: NCT00521989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01059786
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Study: NCT01059786
Drug: Bronchodilators
Normalized name: ANTIASTHMA/BRONCHODILATORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional treatment with bronchodilators may be indicated.
Study: NCT00098228
Drug: QAB149
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00385788
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.
Study: NCT02036463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00384384
Drug: oral 18B Glycyrrhetinic acid versus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01739634
Drug: CASAD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CASAD is provided in 500mg capsules.
Study: NCT02572349
Drug: IW-1701
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02572349
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00483548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo oral capsules to be administered as per the instructions for the ziprasidone arm
Study: NCT01294566
Drug: GSK1322888
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg, 5 mg or 25 mg capsule
Study: NCT01294566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo capsules
Study: NCT00455416
Drug: Omega 3 fatty acids (EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid))
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mgx5 daily
Study: NCT04692025
Drug: ASC41 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT01005706
Drug: rapamune, mycophenolate mofetil and steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator.
Study: NCT04549922
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mL subcutaneous
Study: NCT02062801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received normal saline (placebo) administered immediately after combined spinal epidural (CSE) placement
Study: NCT01466322
Drug: GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four single dosing sessions where each regimen A,B C or D will be administered orally in a randomised, cross-over manner. At each dosing session, pharmacokinetic sampling time-points will be the same.
Study: NCT02507284
Drug: SRX246
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02507284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01258088
Drug: AN2728 Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg/cm2, BID
Study: NCT02290093
Drug: Standard full-volume PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be asked to take 4L of PEG-3350 solution the day prior to procedure.